Stella Xu
Director/Board Member bij DESIGN THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-03-2024
Profiel
Stella Xu is currently the Managing Director at Quan Capital Management LLC, the Independent Director at Design Therapeutics, Inc., the Director at Walking Fish Therapeutics, Inc., the Director at Zidan Medical, Inc., the Director at Therorna, Inc., and the Director at HBM Healthcare Investments AG.
Previously, she served as the Director at TempestTx, Inc., the Director at ARMO BioSciences, Inc., the Independent Director at NextCure, Inc., the Director at Centrexion Therapeutics Corp., the Director at Tempest Therapeutics, Inc., and the Vice President, Site Head-R&D Center China at Roche Innovation Center.
Dr. Xu completed her undergraduate degree at Peking University and her doctorate at Northwestern University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-03-2023 | 579 710 ( 2.61% ) | 2 M $ | 31-03-2024 | |
| 31-03-2023 | 608 ( 0.01% ) | 130 686 $ | 31-03-2024 | |
| 31-05-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Stella Xu
| Bedrijven | Functie | Begin |
|---|---|---|
| DESIGN THERAPEUTICS, INC. | Director/Board Member | 01-03-2020 |
| HBM HEALTHCARE INVESTMENTS AG | Director/Board Member | 01-06-2020 |
| Quan Capital Management LLC | Corporate Officer/Principal | 01-08-2017 |
| Zidan Medical, Inc. | Director/Board Member | 01-11-2018 |
Walking Fish Therapeutics, Inc.
 Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | Director/Board Member | 01-06-2019 |
| Therorna, Inc. | Director/Board Member | - |
Eerdere bekende functies van Stella Xu
| Bedrijven | Functie | Einde |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Director/Board Member | 05-01-2022 |
| CENTREXION THERAPEUTICS CORPORATION | Director/Board Member | 01-01-2022 |
| NEXTCURE, INC. | Director/Board Member | 30-09-2021 |
| ░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Stella Xu
| Peking University | Undergraduate Degree |
| Northwestern University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| NEXTCURE, INC. | Health Technology |
| DESIGN THERAPEUTICS, INC. | Health Technology |
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 9 |
|---|---|
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Health Technology |
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Its product pipeline includes CNTX-4975, CNTX-0290, CNTX-6970, CNTX-2022, CNTX-6016, and intrathecal platform. The company was founded by Sol J. Barer and Jeffrey B. Kindler in February 2013 and is headquartered in Boston, MA. | Health Technology |
HBM Healthcare Investments AG
 HBM Healthcare Investments AG Investment ManagersFinance HBM Healthcare Investments AG is a listed investment company which invests worldwide, primarily focusing on Europe, Asia and North America, in private and public companies in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. It aims to invest mainly in a form of equity, but also considers convertible bonds, debt securities and derivatives. The investment focus is on later stage companies, and participates in follow-on investment rounds, also acquiring majority stake in target companies. It invests also in other funds. | Finance |
ARMO BioSciences, Inc.
 ARMO BioSciences, Inc. Pharmaceuticals: MajorHealth Technology ARMO BioSciences, Inc. develops immunotherapy for the treatment of cancer, cardiovascular diseases, fibrosis, and inflammation. Its lead product candidate is AM0010 (pegilodecaki). The company was founded by Peter Van Vlasselaer, Martin Oft, and John B. Mumm on June 23, 2010 and is headquartered in Redwood, CA. | Health Technology |
| Quan Capital Management LLC | Finance |
| Roche Innovation Center | |
Walking Fish Therapeutics, Inc.
Walking Fish Therapeutics, Inc. BiotechnologyHealth Technology Walking Fish Therapeutics, Inc. engages in the provision of immune therapy services. It offers treatment for oncology, rare deficiency disease, regenerative medicine, and infectious disease. The company was founded by Lewis T. Williams, Mark Selby, Seenu Kothakota, and Tom Brennan and is headquartered in South San Francisco, CA. | Health Technology |
| Zidan Medical, Inc. | |
| Therorna, Inc. |
